Literature DB >> 26611549

Glucocorticoids and Rheumatoid Arthritis.

Joana Fonseca Ferreira1, Alaa Abdelkhalik Ahmed Mohamed2, Paul Emery3.   

Abstract

Glucocorticoids (GCs) were discovered in the 1940s and were administered for the first time to patients with rheumatoid arthritis in 1948. However, side effects were subsequently reported. In the last 7 decades, the mechanisms of action for both therapeutic properties and side effects have been elucidated. Mechanisms for minimizing side effects were also developed. GCs are the most frequently used class of drugs in the treatment of rheumatoid arthritis because of their efficacy in relieving symptoms and their low cost. A review of clinical applications, side effects, and drug interactions is presented.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dose; Drug-drug interactions; Glucocorticoids; Prednisolone; Rheumatoid arthritis; Side effect

Mesh:

Substances:

Year:  2016        PMID: 26611549     DOI: 10.1016/j.rdc.2015.08.006

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  13 in total

Review 1.  Rheumatology in Egypt: back to the future.

Authors:  Tamer A Gheita; Nahla N Eesa
Journal:  Rheumatol Int       Date:  2018-11-07       Impact factor: 2.631

2.  Glucocorticoids improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis.

Authors:  F Verhoeven; P Totoson; K Maguin-Gaté; A Prigent-Tessier; C Marie; D Wendling; J Moretto; C Prati; C Demougeot
Journal:  Clin Exp Immunol       Date:  2017-03-09       Impact factor: 4.330

3.  Structural optimization of HPMA copolymer-based dexamethasone prodrug for improved treatment of inflammatory arthritis.

Authors:  Zhenshan Jia; Gang Zhao; Xin Wei; Dexuan Kong; Yuanyuan Sun; You Zhou; Subodh M Lele; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Dong Wang
Journal:  J Control Release       Date:  2020-05-20       Impact factor: 9.776

4.  The Sesquiterpene Lactone, Budlein A, Inhibits Antigen-Induced Arthritis in Mice: Role of NF-κB and Cytokines.

Authors:  Ana C Zarpelon; Victor Fattori; Fabricio O Souto; Larissa G Pinto; Felipe A Pinho-Ribeiro; Kenji W Ruiz-Miyazawa; Walter M Turato; Thiago M Cunha; Fernando B da Costa; Fernando Q Cunha; Rubia Casagrande; Nilton S Arakawa; Waldiceu A Verri
Journal:  Inflammation       Date:  2017-12       Impact factor: 4.092

5.  Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis.

Authors:  Elisangela Gueiber Montes; Fabiana Postiglioni Mansani; Alceu de Oliveira Toledo Júnior; Marcelo Derbli Schafranski; Bruno Queiroz Zardo; Fábio André Dos Santos; Sabrina Grassiolli; Lorena de Freitas Calixto; Rômulo Lopes da Costa; Felício de Freitas Netto; José Carlos Rebuglio Vellosa
Journal:  Inflammopharmacology       Date:  2021-11-26       Impact factor: 4.473

Review 6.  Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.

Authors:  Ping Li; Ying Zheng; Xin Chen
Journal:  Front Pharmacol       Date:  2017-07-12       Impact factor: 5.810

Review 7.  The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis.

Authors:  Federico Biscetti; Andrea Flex; Stefano Alivernini; Barbara Tolusso; Elisa Gremese; Gianfranco Ferraccioli
Journal:  Mediators Inflamm       Date:  2017-10-23       Impact factor: 4.711

8.  A novel dendritic mesoporous silica based sustained hydrogen sulfide donor for the alleviation of adjuvant-induced inflammation in rats.

Authors:  Yue Yu; Zhou Wang; Qinyan Yang; Qian Ding; Ran Wang; Zhaoyi Li; Yudong Fang; Junyi Liao; Wei Qi; Keyuan Chen; Meng Li; Yi Zhun Zhu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

9.  Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis.

Authors:  Barry Weatherley; Lynn McFadyen; Brinda Tammara
Journal:  Clin Transl Sci       Date:  2017-11-04       Impact factor: 4.689

Review 10.  Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment.

Authors:  Shirin Assar; Hosna Khazaei; Maryam Naseri; Fardous El-Senduny; Saeideh Momtaz; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  J Immunol Res       Date:  2021-06-24       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.